reports
GTT : Q3 2025 Activity Update - Press Release
GTT : Q3 2025 Activity Update - Press Release Revenue of 600 million euros for the first nine months of 2025, strong growth of 29%; annual objectives revised upwards 9M 2025 revenue: 599.6 million euros, up 29.0% vs. 9M 2024; +27.6% at constant scopeOrder intake: 19 LNG carriers, 7 ethane carriers, 1 FLNG, 18 LNG-powered container ships and 1 LNG bunker vesselVery strong pick-up of final investment decisions in LNGAcquisition of Danelec completed on July 31, 20252025 objectives revised upwards: revenue in the range of 790–820 million euros and EBITDA in the range of 530–550 million euros ...
GTT : Activité du 3e trimestre 2025 - Communiqué de Presse
GTT : Activité du 3e trimestre 2025 - Communiqué de Presse Chiffre d’affaires de 600 M€ sur les neuf premiers mois 2025, en forte hausse de 29% ; objectifs annuels revus à la hausse Chiffre d’affaires 9M 2025 : 599,6 M€, +29,0 % vs 9M 2024 ; +27,6 % à périmètre constantNiveau de commandes : 19 méthaniers, 7 éthaniers, 1 FLNG, 18 porte-conteneurs propulsés au GNL et 1 navire de soutage GNLTrès forte reprise des décisions d’investissements dans le GNLAcquisition de Danelec finalisée le 31 juillet 2025Objectifs 2025 revus à la hausse : chiffre d’affaires dans une fourchette de 790 à 820 M€ e...
- Felix Fischer
Europe HY Trade Book - Commercial & Professional Services, Information...
The Europe HY Trade Book - Commercial & Professional Services, Information Technology includes current trade recommendations drawn from our European HY commercial & professional services and information technology coverage universe, along with relative-value scatter plots and a peer table.
- Luis de Toledo Heras
TEMN TEMENOS AG
SOP SOPRA STERIA GROUP SA
OUT1V OUTOKUMPU OYJ
SBMO SBM OFFSHORE NV
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
VETO VETOQUINOL SA
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
NOEJ NORMA GROUP SE
BB SOCIETE BIC SA
BAMNB KONINKLIJKE BAM GROEP NV
VID VIDRALA SA
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
SHOT SCANDIC HOTELS GROUP
WAF SILTRONIC AG
MELE MELEXIS NV
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
ALR ALIOR BANK SA
CSM CORBION NV
SAE SHOP APOTHEKE EUROPE NV
ALD ALD SA
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ALLFG ALLFUNDS (UK) LTD
ORP ORPEA
SHA SCHAEFFLER AG
- Carole Braudeau
- Luis de Toledo Heras
TEMN TEMENOS AG
SOP SOPRA STERIA GROUP SA
OUT1V OUTOKUMPU OYJ
SBMO SBM OFFSHORE NV
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
VETO VETOQUINOL SA
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
NOEJ NORMA GROUP SE
BB SOCIETE BIC SA
BAMNB KONINKLIJKE BAM GROEP NV
VID VIDRALA SA
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
SHOT SCANDIC HOTELS GROUP
WAF SILTRONIC AG
MELE MELEXIS NV
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
ALR ALIOR BANK SA
CSM CORBION NV
SAE SHOP APOTHEKE EUROPE NV
ALD ALD SA
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ALLFG ALLFUNDS (UK) LTD
ORP ORPEA
SHA SCHAEFFLER AG
- Jean-François Granjon
- Jean-François Granjon
Inventiva: 1 director
A director at Inventiva bought 24,700 shares at 3.295EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Inventiva Announces the Implementation of a New ATM Program
Inventiva Announces the Implementation of a New ATM Program Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”). The Registration Statement includes a base prospectus and a sales agreement ...
Inventiva annonce la mise en place d’un nouveau programme « At-The-Mar...
Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM) Daix (France), New York City (New York, Etats-Unis), le 14 octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce ce jour avoir enregistré un document préalable intitulé « Form F-3 » (le « Document d’Enregistrement »), auprès de la U.S. Securities and Exchange Commission (« SEC »), aux Etats...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
Inventiva CMD outlines lanifibranor's differentiation in MASH
Yesterday, Inventiva hosted a CMD which highlighted the potential of lanifibranor in MASH. Our main takeaways are i) the number of diagnosed/treated MASH patients is on the rise, a trend that is expected to continue, ii) the future of the MASH landscape will involve combination therapies with GLP-1 likely being the backbone, and iii) lanifibranor is well positioned to reach a broader set of prescribers incl. endocrinologists thanks to its mechanism and metabolic benefits. We reiterate our € 8 TP...
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 20...
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital pathology data from preclinical studies with lanifibranor Daix (France), New York City (New York, United States), October 7, 2025 - (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announc...
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liv...
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liver Meeting® 2025 Présentation d’une comparaison entre histologie numérique et sur lame des biopsies de screening de l’étude de Phase 3 NATiV3Présentation de pathologie numérique de données précliniques avec lanifibranor Daix (France), New York City (New York, United States), le 7 octobre, 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnemen...
GTT: Monthly disclosure of the total number of voting rights and share...
GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Monthly disclosure of the total number of voting rights and shares composing the share capital Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, October 3, 2025 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2September 30, 202537,117,77237,117,77237,064,515 Investor Relations Contact / 87 1 Calculat...
GTT : Information mensuelle relative au nombre total de droits de vote...
GTT : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 3 octobre 2025 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets230 septembre 202537 117 77237 117 77237 064 515 Contact Relations Investisseurs : / 87 ...
- Carole Braudeau
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.